Get our free email newsletter

Batteries in Implantable Defibrillators May Fail

The U.S. Food and Drug Administration (FDA) and medical device manufacturer St. Jude Medical of St. Paul, MN are warning healthcare providers and patients about potential life-threatening problems with batteries in the company’s implantable defibrillators.

According to a medical advisory issued this week by the FDA, the integrated batteries in the defibrillators may lose power much more quickly than the normal three-month lead time indicated by the device’s elective replacement indicator (ERI). The problem is reportedly linked to deposits of lithium that form within the battery, creating abnormal electrical conditions that result in rapid battery failure. In some cases, batteries have reportedly lost power within 24 hours of the patient first receiving an ERI alert.

The FDA estimates that nearly 350,000 of the affected defibrillators are implanted in patients worldwide. The Wall Street Journal reports that two patients died when battery power in their implanted defibrillators was insufficient to power the devices, preventing them from providing the required shock therapy.

- Partner Content -

Shielding Effectiveness Test Guide

Just as interference testing requires RF enclosures, isolation systems in turn need their own testing. This document reviews some of the issues and considerations in testing RF enclosures.

Read the complete text of the FDA’s medical advisory, including recommendations for healthcare professionals.

Related Articles

Digital Sponsors

Become a Sponsor

Discover new products, review technical whitepapers, read the latest compliance news, and check out trending engineering news.

Get our email updates

What's New

- From Our Sponsors -

Sign up for the In Compliance Email Newsletter

Discover new products, review technical whitepapers, read the latest compliance news, and trending engineering news.